<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01332162</url>
  </required_header>
  <id_info>
    <org_study_id>CRT-01-2011-HCPB</org_study_id>
    <nct_id>NCT01332162</nct_id>
  </id_info>
  <brief_title>CArdiac Desynchronization In Obstructive HCM, CARDIO-HCM</brief_title>
  <acronym>CARDIO-HCM</acronym>
  <official_title>CArdiac Desynchronization In Obstructive Hypertrophic CardioMyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the benefit of the optimal pacing configuration,
      including the possibility of biventricular or left ventricular pacing, in hypertrophic
      obstructive cardiomyopathy patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, subjects will be randomized to Cardiac Resynchronization
      Therapy-Defibrillation (CRT-D) or Cardiac Resynchronization Therapy-Pacing (CRT-P) vs Pacing
      Therapy AAI. Randomization will be stratified by indication. Optimal pharmacological therapy
      in both treatment arms. Length of follow-up for each subject will be 2y, since all subjects
      will be followed to a common study termination date.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Left ventricular mass and resting left ventricular outflow tract gradient (mmHg).</measure>
    <time_frame>1 and 2 years</time_frame>
    <description>Change from Baseline in Left ventricular mass and resting left ventricular outflow tract gradient (mmHg)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Clinical evaluation of NYHA,QoL,6MWT,interventricular septum thickness,posterior wall thickness,provoked left ventricular outflow tract gradient,mitral regurgitation grade.</measure>
    <time_frame>1 and 2 years</time_frame>
    <description>Change from Baseline in Clinical evaluation (New York Heart Association(NYHA), Quality of life Questionnaire (QoL), 6 Minutes Walk Test (6MWT)), interventricular septum thickness, posterior wall thickness, provoked left ventricular outflow tract gradient, mitral regurgitation grade.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Hypertrophic Obstructive Cardiomyopathy (HOCM)</condition>
  <arm_group>
    <arm_group_label>Biventricular pacing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will be pacing during two years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Pacing during the first year</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>No Pacing during the first year. In the second year all patients will be pacing</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Biventricular pacing</intervention_name>
    <description>All patients will be pacing during two years</description>
    <arm_group_label>Biventricular pacing</arm_group_label>
    <other_name>CRT-D and CRT-P devices:</other_name>
    <other_name>Promote Quadra CD3239-40, CD3239-40Q. St. Jude Medical</other_name>
    <other_name>Promote Q CD3221-36. St. Jude Medical</other_name>
    <other_name>Pacemaquer:</other_name>
    <other_name>Anthem PM3112. St. Jude Medical</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>No Pacing</intervention_name>
    <description>No Pacing during the first year. In the second year all patients will be pacing</description>
    <arm_group_label>No Pacing during the first year</arm_group_label>
    <other_name>CRT-D and CRT-P devices:</other_name>
    <other_name>Promote Quadra CD3239-40, CD3239-40Q. St. Jude Medical</other_name>
    <other_name>Promote Q CD3221-36. St. Jude Medical</other_name>
    <other_name>Pacemaquer:</other_name>
    <other_name>Anthem PM3112. St. Jude Medical</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with hypertrophic Obstructive Cardiomyopathy with significant left
             ventricular obstruction (baseline LVOT gradient more 50mmHg and severe symptoms

        Exclusion Criteria:

          -  HOCM intraventricular gradient &lt; 50mmHg

          -  LV ejection fraction &lt; 50%

          -  mild symptoms
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JOSEP BRUGADA, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ANTONIO BERRUEZO, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOSPITAL CL√çNIC DE BARCELONA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Josep Brugada, MD. PhD.</last_name>
      <phone>+34932275703</phone>
      <email>jbrugada@clinic.ub.es</email>
    </contact>
    <contact_backup>
      <last_name>Dr.Antonio Berruezo, MD. PhD.</last_name>
      <phone>+34 93 2275551</phone>
      <email>aberruezo@clinic.ub.es</email>
    </contact_backup>
    <investigator>
      <last_name>Dr. Josep Brugada, MD. PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2011</study_first_submitted>
  <study_first_submitted_qc>April 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2011</study_first_posted>
  <last_update_submitted>October 19, 2016</last_update_submitted>
  <last_update_submitted_qc>October 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>Josep Brugada</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Hypertrophic Obstructive Cardiomyopathy (HOCM)</keyword>
  <keyword>Pacing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Cardiomyopathy, Hypertrophic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

